AVIR Stock Summary and Trading Ideas (Atea Pharmaceuticals | NASDAQ:AVIR)

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Atea Pharmaceuticals trades on the NASDAQ stock market under the symbol AVIR.

As of July 28, 2026, AVIR stock price declined to $4.51 with 1,209,418 million shares trading.

AVIR has a beta of 0.71, meaning it tends to be less sensitive to market movements. AVIR has a correlation of 0.02 to the broad based SPY ETF.

AVIR has a market cap of $360.92 million. This is considered a Small Cap stock.

In the last 3 years, AVIR traded as high as $6.45 and as low as $2.46.

The top ETF exchange traded funds that AVIR belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

AVIR has underperformed the market in the last year with a price return of +15.6% while the SPY ETF gained +17.5%. AVIR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.9% and -4.9%, respectively, while the SPY returned +3.9% and -1.1%, respectively.

AVIR support price is $4.67 and resistance is $4.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVIR shares will trade within this expected range on the day.